Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- RFIL +40.6%, CAL +8.6%, EXPR +8.1%, PETQ +7.7%, MDB +5.7%, VYGR +2.4%, TOUR+2.2%, NTRA +2.1%, SENS +1.6%, BLCM +1.5%, CLSD +1.4%
Other news:
- KOOL +11.5% (has signed a license agreement with IncoCell Tianjin Ltd., a wholly-owned subsidiary of China-based Boyalife Group, for CAR-T related and other cellular processing CDMO services)
- TRIL +8.6% (granted orphan drug designation by the FDA for its compound for the treatment of Cutaneous T-Cell Lymphoma)
- CWH +5.2% (files amended 10-Q with restatements and files previously delayed 10-K)
- VRX +2% (CEO disclosed purchase of 30000 shares worth ~$482K and CFO purchased of 15000 shares worth)
- AMR +0.6% (Point72 Asset Management unveils 5% passive stake)
Analyst comments:
- F +3.7% (upgraded to Overweight at Morgan Stanley)
- CDMO +3.4% (initiated with Overweight and $4 tgt at First Analysis after the close)
- CRH +2.2% (upgraded to Outperform from Neutral at Exane BNP Paribas)